» Articles » PMID: 8976723

Risk Factors for Herpes Simplex Virus Epithelial Keratitis Recurring During Treatment of Stromal Keratitis or Iridocyclitis. Herpetic Eye Disease Study Group

Overview
Journal Br J Ophthalmol
Specialty Ophthalmology
Date 1996 Nov 1
PMID 8976723
Citations 51
Authors
Affiliations
Soon will be listed here.
Abstract

Aims: Possible risk factors were evaluated for herpes simplex virus (HSV) epithelial keratitis in patients with stromal keratouveitis.

Methods: The study population included 260 patients who had active stromal keratitis and/or iridocyclitis without epithelial disease and who were enrolled in one of three clinical trials of the Herpetic Eye Disease Study. Study treatment involved a 10 week course of topical placebo, topical prednisolone phosphate, or topical prednisolone phosphate with oral acyclovir. All groups received topical trifluridine four times daily for 3 weeks then twice daily for another 7 weeks. Patients were examined for HSV epithelial keratitis for 16 weeks.

Results: Dendritic or geographic epithelial keratitis occurred in 12 (4.6%) study patients. Adverse effects attributable to trifluridine prophylaxis were acute allergic blepharoconjunctivitis in 10 (3.8%) study patients and corneal epithelial erosions in 11 (4.2%) study patients. No significant difference in the occurrence of HSV epithelial keratitis was found among the study treatment groups: one (2.0%) of 49 topical placebo treated patients, nine (6.5%) of 138 patients treated with topical corticosteroids without acyclovir, and two (2.7%) of 73 patients treated with topical corticosteroids and oral acyclovir. Univariate exponential models suggested that patients with a history of previous HSV epithelial keratitis and non-white patients were more likely to develop HSV epithelial keratitis during treatment of stromal keratouveitis.

Conclusion: Individuals with prior HSV epithelial keratitis and certain ethnic groups may have a higher rate of recurrent epithelial keratitis during the acute treatment of HSV stromal keratouveitis.

Citing Articles

Drug delivery strategies to improve the treatment of corneal disorders.

Tafti M, Fayyaz Z, Aghamollaei H, Jadidi K, Faghihi S Heliyon. 2025; 11(2):e41881.

PMID: 39897787 PMC: 11783021. DOI: 10.1016/j.heliyon.2025.e41881.


Possible viral agents to consider in the differential diagnosis of blepharoconjunctivitis.

Musa M, Bale B, Suleman A, Aluyi-Osa G, Chukwuyem E, DEsposito F World J Virol. 2024; 13(4):97867.

PMID: 39722756 PMC: 11551683. DOI: 10.5501/wjv.v13.i4.97867.


Presence of CD80 and Absence of LAT in Modulating Cellular Infiltration and HSV-1 Latency.

Jaggi U, Ghiasi H Viruses. 2024; 16(9).

PMID: 39339855 PMC: 11436179. DOI: 10.3390/v16091379.


The anti-apoptotic function of HSV-1 LAT in neuronal cell cultures but not its function during reactivation correlates with expression of two small non-coding RNAs, sncRNA1&2.

Oh J, Jaggi U, Tormanen K, Wang S, Hirose S, Ghiasi H PLoS Pathog. 2024; 20(6):e1012307.

PMID: 38857310 PMC: 11192303. DOI: 10.1371/journal.ppat.1012307.


Clinical and Demographic Characteristics of Herpetic Keratitis Patients-Tertiary Centre Experience.

Grubesic P, Jurak I, caljkusic-Mance T, Belancic A, Grubesic A Medicina (Kaunas). 2024; 60(4).

PMID: 38674223 PMC: 11052461. DOI: 10.3390/medicina60040577.


References
1.
Patterson A, Jones B . The management of ocular herpes. Trans Ophthalmol Soc U K (1962). 1967; 87:59-84. View

2.
Sundmacher R . [Trifluorothymidin-prophylaxis of dendritic keratitis in steroid-treated herpetic keratouveitis (author's transl)]. Klin Monbl Augenheilkd. 1978; 173(4):516-9. View

3.
Hung S, Patterson A, Rees P . Pharmacokinetics of oral acyclovir (Zovirax) in the eye. Br J Ophthalmol. 1984; 68(3):192-5. PMC: 1040285. DOI: 10.1136/bjo.68.3.192. View

4.
Collum L, McGettrick P, Akhtar J, Lavin J, Rees P . Oral acyclovir (Zovirax) in herpes simplex dendritic corneal ulceration. Br J Ophthalmol. 1986; 70(6):435-8. PMC: 1041036. DOI: 10.1136/bjo.70.6.435. View

5.
Kaufman H, MARTOLA E, Dohlman C . Herpes simplex treatment with IDU and corticosteroids. Arch Ophthalmol. 1963; 69:468-72. DOI: 10.1001/archopht.1963.00960040474008. View